There has been a rise in interest in buccal medication administration for its potential to produce either local or systemic effects. The buccal mucosa may be used to apply and remove dosing forms in emergency situations involving toxicity. Patients with insufficient control of, or intolerance to, first-line medications may benefit from prophylactic and symptomatic therapy with Trimetazidine for stable angina pectoris. Polymers like HPMC and Sodium Alginate were used to make the mucoadhesive buccal tablets. As a result of Response Surface analysis, the formulation has been fine-tuned. According to FTIR analyses, the pure medicine and excipients did not react chemically with one another. The tablets were made using a direct compression approach. Optimal Formulation F1 Has a High Mucoadhesive Property. According to the Optimizing research, after 9 hours, F1 shows a maximum of 89% drug release. And a 98.75% assay value was determined.